Novocure Ltd. reported preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2025. The company recorded total preliminary net revenues of $655.4 million for the year, marking an 8% increase compared to the prior year. For the fourth quarter, total preliminary net revenues were $174.4 million, also reflecting an 8% increase from the same period in 2024. In the fourth quarter, net revenue contributions by market included $101.6 million from the U.S., $21.6 million from Germany, $20.5 million from France, and $10.2 million from Japan. Other active markets contributed $15.8 million, while revenue from Greater China, through Novocure's partnership with Zai Lab, totaled $4.6 million. Recognized revenue from Optune Lua® in the quarter was $3.5 million, with $2.4 million from non-small cell lung cancer (NSCLC) and $1.1 million from malignant pleural mesothelioma (MPM). The company stated it is positioned for multiple product launches in 2026 and is focused on achieving profitability. Novocure will hold a conference call and webcast to discuss these results on February 26, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112061741) on January 12, 2026, and is solely responsible for the information contained therein.